Radiation With Immunotherapy May Be a Double-Edged Sword—How Can We Learn From Recent Negative Clinical Trials?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Radiation With Immunotherapy May Be a Double-Edged Sword—How Can We Learn From Recent Negative Clinical Trials?

Published:2024-08-01 Issue:8 Volume:10 Page:1019
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

McGee Heather M.¹²,Williams Terence M.¹³,Lee Percy⁴

Affiliation:

1. Department of Radiation Oncology, City of Hope National Medical Center, Duarte, California

2. Department of Immuno-Oncology, Beckman Research Institute of City of Hope, Duarte, California

3. Department of Cancer Genetics & Epigenetics, Beckman Research Institute of City of Hope, Duarte, California

4. Department of Radiation Oncology, City of Hope Orange County, Irvine, California

Abstract

This Viewpoint explains differences between recent studies using radiotherapy with immunotherapy and possible reasons for their different outcomes.

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2819646/jamaoncology_mcgee_2024_vp_240009_1723659857.34632.pdf

Reference7 articles.

1. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.;Antonia;N Engl J Med,2018

2. Sequence of aPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses.;Wei;Sci Immunol,2021

3. Biological dosimetry: the potential use of radiation-induced apoptosis in human T-lymphocytes.;Menz;Radiat Environ Biophys,1997

4. Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial.;Monjazeb;Nat Commun,2023

5. Safety and efficacy results from iSABR, a phase 1 study of stereotactic ablative radiotherapy in combination with durvalumab for early-stage medically inoperable non-small cell lung cancer.;Wu;Int J Radiat Oncol Biol Phys,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3